WAP
ICPT

Wealthcare Advisory Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Wealthcare Advisory Partners’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,307
Closed -$76K – 2000
2021
Q1 		$76K Buy
+3,307
New +$92.2K 0.01% 755

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Wealthcare Advisory Partners's ICPT Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2021, closing a stake of 3,307 shares — an estimated $76K sold.

Wealthcare Advisory Partners first reported a position in ICPT in Q1 2021 and held it in 1 quarter. The position peaked at $76K in Q1 2021. 129 funds tracked by Wall St. Rank hold ICPT as of Q2 2021.

  • Wealthcare Advisory Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 3,307 Intercept Pharmaceuticals, Inc. shares in Q2 2021, an estimated $76K.
  • Wealthcare Advisory Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Wealthcare Advisory Partners's Intercept Pharmaceuticals, Inc. position peaked at $76K in Q1 2021.
  • 129 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.